viewAntibe Therapeutics Inc

Antibe Therapeutics hosts successful annual and special general meeting

The firm said shareholders elected six directors at its annual general meeting

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging efficacy study for the drug remains on track

Antibe Therapeutics (CVE:ATE) (OTCMKTS:ATBPF) released a shareholder update Tuesday, which highlighted its annual general and special meeting, noting all resolutions outlined in the management information circular were approved. 

The firm noted shareholders elected a number of directors: Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu. 

Shareholders also approved the reappointment of Ernst & Young LLP, Chartered Accountants, as Antibe's auditor, as well as an amendment to the restricted share unit plan. 

READ: Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track.

The firm is developing a platform of unique drugs to prevent gastrointestinal damage and bleeding caused by using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief. 

Shares of Antibe were at C$0.32 on Tuesday. 

Contact Katie Lewis at katie@proactiveivestors.com

Quick facts: Antibe Therapeutics Inc

Price: - -

Market: TSX-V
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...


Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 12/8/20

2 min read